Abstract:
BACKGROUND:In China, there are currently no approved therapies for the treatment of metastatic renal cell carcinoma (mRCC) following progression with vascular endothelial growth factor (VEGF)-targeted agents. In the phase 3 RECORD-1 trial, the mammalian target of rapamycin (mTOR) inhibitor everolimus afforded clinical benefit with good tolerability in Western patients with mRCC whose disease had progressed despite VEGF receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy. This phase 1b study was designed to further evaluate the safety and efficacy of everolimus in VEGFr-TKI-refractory Chinese patients with mRCC. METHODS:An open-label, multicenter phase 1b study enrolled Chinese patients with mRCC who were intolerant to, or progressed on, previous VEGFr-TKI therapy (N = 64). Patients received everolimus 10 mg daily until objective tumor progression (according to RECIST, version 1.0), unacceptable toxicity, death, or study discontinuation for any other reason. The final data analysis cut-off date was November 30, 2011. RESULTS:A total of 64 patients were included in the study. Median age was 52 years (range, 19-75 years) and 69% of patients were male. Median duration of everolimus therapy was 4.1 months (range, 0.0-16.1 months). Expected known class-effect toxicities related to mTOR inhibitor therapy were observed, including anemia (64%), hypertriglyceridemia (55%), mouth ulceration (53%), hyperglycemia (52%), hypercholesterolemia (50%), and pulmonary events (31%). Common grade 3/4 adverse events were anemia (20%), hyperglycemia (13%), increased gamma-glutamyltransferase (11%), hyponatremia (8%), dyspnea (8%), hypertriglyceridemia (6%), and lymphopenia (6%). Median PFS was 6.9 months (95% CI, 3.7-12.5 months) and the overall tumor response rate was 5% (95% CI, 1-13%). The majority of patients (61%) had stable disease as their best overall tumor response. CONCLUSIONS:Safety and efficacy results were comparable to those of the RECORD-1 trial. Everolimus is generally well tolerated and provides clinical benefit to Chinese patients with anti-VEGF-refractory mRCC. TRIAL REGISTRATION:clinicaltrials.gov, NCT01152801.
journal_name
BMC Cancerjournal_title
BMC cancerauthors
Guo J,Huang Y,Zhang X,Zhou F,Sun Y,Qin S,Ye Z,Wang H,Jappe A,Straub P,Pirotta N,Gogov Sdoi
10.1186/1471-2407-13-136subject
Has Abstractpub_date
2013-03-21 00:00:00pages
136issn
1471-2407pii
1471-2407-13-136journal_volume
13pub_type
杂志文章,多中心研究相关文献
BMC CANCER文献大全abstract:BACKGROUND:The aim of this study was to determine the safety and efficacy of fractionated stereotactic radiotherapy (SRT) in combination with systemic therapies (ST) for brain metastases (BM). METHODS:Ninety-nine patients (171 BM) received SRT and concurrent ST (group 1) and 95 patients (131 BM) received SRT alone wit...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-020-07491-z
更新日期:2020-10-13 00:00:00
abstract:BACKGROUND:Circulating tumor cells (CTCs) are detectable in peripheral blood of metastatic breast cancer patients (MBC). In this paper we evaluate a new CTC separation method based on a combination of anti-EpCAM- and anti-cytokeratin magnetic cell separation with the aim to improve CTC detection with low target antigen...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-12-206
更新日期:2012-05-30 00:00:00
abstract:BACKGROUND:To validate the robust predictive values of tumor vascularity and hand-foot-skin reaction (HFSR) in combination treatment of transarterial chemoembolization (TACE) and sorafenib for patients with intermediate hepatocellular carcinoma (HCC), and then select the potential candidates who would survive best from...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-019-5570-z
更新日期:2019-04-30 00:00:00
abstract:BACKGROUND:Bowel cancer is common and is a major cause of death. Most people with bowel symptoms who meet the criteria for urgent referral to secondary care will not be found to have bowel cancer, and some people who are found to have cancer will have been referred routinely rather than urgently. If general practitione...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-6-251
更新日期:2006-10-23 00:00:00
abstract:BACKGROUND:PRDM5 is an epigenetic regulator that has been recognized as an important tumour suppressor gene. Silencing of PRDM5 by promoter hypermethylation has been demonstrated in several cancer types and PRDM5 loss results in upregulation of the Wnt pathway and increased cellular proliferation. PRDM5 has not been ex...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-015-1011-9
更新日期:2015-01-23 00:00:00
abstract:BACKGROUND:Genome wide association studies (GWAS) have identified several genetic variants that are associated with prostate cancer. Most of these variants, like other GWAS association signals, are located in non-coding regions of potential candidate genes, and thus could act at the level of the mRNA transcript. METHO...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-10-315
更新日期:2010-06-22 00:00:00
abstract:BACKGROUND:BRAF-activated noncoding RNA (BANCR) is aberrantly expressed in various tumor tissues and has been confirmed to function as a tumor suppressor or oncogene in many types of cancers. Considering the conflicting results and insufficient sampling, a meta-analysis was performed to explore the prognostic value of ...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-020-07177-6
更新日期:2020-09-09 00:00:00
abstract:BACKGROUND:Mantle Cell Lymphoma (MCL) is often associated with progression, temporary response to therapy and a high relapse rate over time resulting in a poor long-term prognosis. Because MCL is classified as an incurable disease, therapeutic resistance is of great interest. However, knowledge about the biological mec...
journal_title:BMC cancer
pub_type: 杂志文章,多中心研究
doi:10.1186/s12885-016-2844-6
更新日期:2016-10-14 00:00:00
abstract:BACKGROUND:Reprogramming energy metabolism has been an emerging hallmark of cancer cells. MicroRNAs play important roles in glucose metabolism. METHODS:The targets of microRNA-26a (miR-26a) were predicted by bioinformatics tools. The efficacy of miR-26a binding the 3'-untranslated region (UTR) of pyruvate dehydrogenas...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-14-443
更新日期:2014-06-16 00:00:00
abstract:BACKGROUND:To investigate whether MRI findings, including texture analysis, can differentiate KRAS mutation status in rectal cancer. METHODS:Totally, 158 patients with pathologically proved rectal cancers and preoperative pelvic MRI examinations were enrolled. Patients were stratified into two groups: KRAS wild-type g...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-019-6341-6
更新日期:2019-11-14 00:00:00
abstract:BACKGROUND:Platelets are frequently altered in hepatocellular carcinoma (HCC) patients. Platelet lysates (hPL) can enhance HCC cell growth and decrease apoptosis. The aims were to evaluate whether hPL can modulate the actions of sorafenib or regorafenib, two clinical HCC multikinase antagonists. METHODS:Several human ...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-14-351
更新日期:2014-05-21 00:00:00
abstract:BACKGROUND:Genistein has been known to inhibit proliferation and induce apoptosis in several kinds of cancer cells. While knowledge of genistein in regulating epithelial mesenchymal transition (EMT) of colon cancer cells is unknown. METHODS:To investigate the effects and mechanisms of genistein on EMT of colon cancer ...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-017-3829-9
更新日期:2017-12-04 00:00:00
abstract:BACKGROUND:Frequent failure and severe side effects of current sarcoma therapy warrants new therapeutic approaches. The small-molecule MDM2 antagonist Nutlin-3a activates the p53 pathway and efficiently induces apoptosis in tumours with amplified MDM2 gene and overexpression of MDM2 protein. However, the majority of hu...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-11-211
更新日期:2011-05-30 00:00:00
abstract:BACKGROUND:Subsyndromal delirium, a condition in which patients exhibit some, but not all, of the symptoms of delirium, can negatively affect the outcomes of patients with cancer. However, the incidence of subsyndromal delirium in patients with gastric cancer is unknown. Here, we investigated the incidence and risk fac...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-018-4681-2
更新日期:2018-07-27 00:00:00
abstract:BACKGROUND:Cytokines are involved in cancer invasion and metastasis. Circulating tumor cells (CTCs) play key role in tumor dissemination and are an independent survival predictor in breast cancer patients. The aim of this study was to assess correlation between CTCs and plasma cytokines in primary breast cancer (PBC) p...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-016-2143-2
更新日期:2016-02-19 00:00:00
abstract:BACKGROUND:Aprepitant is an FDA-approved medication for chemotherapy-induced nausea and vomiting. It blocks substance P binding to neurokinin-1; substance P has been implicated in itch pathways both as a local and global mediator. CASE PRESENTATIONS:We report a series of four patients, diagnosed with cutaneous T-cell ...
journal_title:BMC cancer
pub_type: 杂志文章,meta分析
doi:10.1186/s12885-017-3194-8
更新日期:2017-03-16 00:00:00
abstract:BACKGROUND:Patients with advanced or metastatic non-small cell lung cancer (NSCLC) can develop acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib. Here, we report the successful treatment with alternating chemotherapy and TKIs of two cases of advanced NSCLC...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-11-90
更新日期:2011-03-02 00:00:00
abstract:BACKGROUND:Severe toxicity to 5-fluorouracil (5-FU) based chemotherapy in gastrointestinal cancer has been associated with constitutional genetic alterations of the dihydropyrimidine dehydrogenase gene (DPYD). METHODS:In this study, we evaluated DPYD promoter methylation through quantitative methylation-specific PCR a...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-10-470
更新日期:2010-09-01 00:00:00
abstract:BACKGROUND:Suppressors of cytokine signaling (SOCS) are important negative feedback regulators of the JAK/STAT signaling pathway, and have been recently investigated for their role in the development of different cancers. In this study, we examined the expression of SOCS1-7 genes in normal and breast cancer tissue and ...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-10-178
更新日期:2010-04-30 00:00:00
abstract:BACKGROUND:RASSF1A gene silencing by DNA methylation has been suggested as a major event in pancreatic endocrine tumor (PET) but RASSF1A expression has never been studied. The RASSF1 locus contains two CpG islands (A and C) and generates seven transcripts (RASSF1A-RASSF1G) by differential promoter usage and alternative...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-11-351
更新日期:2011-08-12 00:00:00
abstract:BACKGROUND:Cytochrome P450 1B1 (CYP1B1) has been shown to be up-regulated in many types of cancer including renal cell carcinoma (RCC). Several reports have shown that CYP1B1 can influence the regulation of tumor development; however, its role in RCC has not been well investigated. The aim of the present study was to d...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-015-1951-0
更新日期:2015-12-01 00:00:00
abstract:BACKGROUND:Breast metastasis from lung cancer has been reported, but not from SCLC that is transformed from lung adenocarcinoma during maintenance treatment with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). Transformation to small cell lung cancer(SCLC), although uncommonly seen, has been asso...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-016-2623-4
更新日期:2016-08-03 00:00:00
abstract:BACKGROUND:The failure of treatment for breast cancer usually results from distant metastasis in which the epithelial-mesenchymal transition (EMT) plays a critical role. Hyperinsulinemia, the hallmark of Type 2 diabetes mellitus (T2DM), has been regarded as a key risk factor for the progression of breast cancer. Nuclea...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-020-07107-6
更新日期:2020-07-06 00:00:00
abstract:BACKGROUND:Systemic inflammation has been implicated in cancer development and progression. This study examined the best cutoff value of erythrocyte sedimentation rate (ESR) in diffuse large B-cell lymphoma (DLBCL) patients. METHODS:The relationship between ESR and clinical characteristics was analyzed in 182 DLBCL pa...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-018-4914-4
更新日期:2018-10-19 00:00:00
abstract:BACKGROUND:Methylation of promoter region is the major mechanism affecting gene expression in tumors. Recent methylome studies of brain tumors revealed a list of new epigenetically modified genes. Our aim was to study promoter methylation of newly identified epigenetically silenced genes together with already known epi...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-12-218
更新日期:2012-06-06 00:00:00
abstract:BACKGROUND:In general, human papillomavirus (HPV) vaccines have demonstrated efficacy in young women worldwide, but there is limited evidence on the efficacy of the quadrivalent HPV6/11/16/18 vaccine in adult women and no evidence of its effectiveness in Japanese adult women in particular. This study aims to evaluate t...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-020-07563-0
更新日期:2020-11-03 00:00:00
abstract:BACKGROUND:The incidence and survival of melanoma are increasing, but little is known about its long-term health effects in adult survivors. METHODS:A health survey was available from 996 melanoma survivors (577 treated with surgery alone, and 391 with combined treatments). Their medical/physiologic and psychosocial r...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-6-95
更新日期:2006-04-18 00:00:00
abstract:BACKGROUND:Long-term survival in numerous cancers often correlates with specific whole transcriptome profiles or the expression patterns of smaller numbers of transcripts. In some instances, these are better predictors of survival than are standard classification methods such as clinical stage or hormone receptor statu...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-020-06756-x
更新日期:2020-04-07 00:00:00
abstract:BACKGROUND:Although advanced-stage cervical cancer can benefit from current treatments, approximately 30% patients may fail after definitive treatment eventually. Therefore, exploring alternative molecular therapeutic approaches is imperatively needed for this disease. We have recently shown that activation of AMP-acti...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-13-327
更新日期:2013-07-03 00:00:00
abstract:BACKGROUND:Suppressor of cytokine signaling (SOCS) proteins comprise a protein family, which has initially been described as STAT induced inhibitors of the Jak/Stat pathway. Recent in vivo and in vitro studies suggest that SOCS proteins are also implicated in cancer. The STAT5 induced IGF-I acts as an endocrine and par...
journal_title:BMC cancer
pub_type: 杂志文章,多中心研究
doi:10.1186/1471-2407-7-136
更新日期:2007-07-25 00:00:00